Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study

PURPOSECyclin inhibitors plus endocrine therapy represent the reference standard for hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) locally advanced or metastatic breast cancer (ABC). Efficacy results on hard end points such as overall survival come from we...

Full description

Bibliographic Details

Published in:	JCO Global Oncology
Main Authors:	Daniele Assad Suzuki, Alessandra Menezes Morelle, Mayana Lopes de Brito, Flavia Rocha Paes, André Mattar, Jorge H. Santos Leal, Sérgio D. Simon, Ellias Magalhães Abreu Lima, Gustavo Werutsky, Gustavo H. Munhoz Piotto, José Bines, Lucas Petri Damiani, Ariane Macedo, Lígia Campos, Anna Maria Buehler
Format:	Article
Language:	English
Published:	American Society of Clinical Oncology 2024-04-01
Online Access:	https://ascopubs.org/doi/10.1200/GO.23.00484